摘要
目的 通过动物实验了解 5α 还原酶抑制剂对前列腺增生新生血管形成的影响 ,为临床治疗提供实验依据。 方法 雄性SD大鼠 6 0只 ,随机分为正常对照组、增生对照组、增生中服药组和增生后服药组 ,增生组均由睾酮诱导前列腺增生 ,增生中服药组在注射睾酮第 2天给予爱普列特 ,增生后服药组在注射睾酮后 2 0d给予爱普列特。实验后各组大鼠处死取材 ,称取前列腺重量 ,行HE染色和第Ⅷ因子、增殖细胞核抗原 (PCNA)及血管内皮生长因子 (VEGF)免疫组化染色检查。 结果 经睾酮诱导后 2 0d前列腺重量测定及组织学检查显示增生组均出现前列腺增生 ,免疫组化显示增生中服药组及增生后服药组与增生对照组的Ⅷ因子、PCNA和VEGF表达结果相比差异有显著性 (P <0 0 5 )。 结论 5α 还原酶抑制剂不仅可有效的抑制前列腺增生过程中的血管形成 ,还可使已形成的微血管减少 ,其对血管形成的影响作用为前列腺增生时血尿的治疗提供了新的研究途径。
Objective To evaluate the effect of 5α reductase inhibitor on vascularity of benign prostatic hyperplasia (BPH). Methods Sixty male adult rats were randomly divided into 4 groups (15 per group): normal control, BPH control group, the group of 5α reductase inhibitor treatment during hyperplasia and the group of treatment after hyperplasia. Immunohistochemistry combined with computer assisted image analysis system were performed to examine the expression of factor Ⅷ related antigen, PCNA and VEGF in the prostatic tissue for all rats. Results The microvessel density(MVD) and the expressions of PCNA and VEGF were much less in treatment during hyperplasia and treatment after hyperplusia than that in BPH control group( P <0 01). Conclusions 5α reductase inhibitor had a significant inhibit efficacy to vascularity in BPH and may be a useful drug for the treatment of the hematuria associated with BPH.
出处
《中华老年医学杂志》
CAS
CSCD
北大核心
2003年第4期237-239,共3页
Chinese Journal of Geriatrics
